株式会社PRISM BioLab Logo

株式会社PRISM BioLab

A biotech creating novel drugs by targeting previously "undruggable" protein interactions.

206A | T

Overview

Corporate Details

ISIN(s):
JP3833190006
LEI:
Country:
Japan
Address:
藤沢市村岡東二丁目26番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

PRISM BioLab is a biotechnology company dedicated to creating novel small molecule drugs for diseases that currently lack effective treatments. The company's core is its proprietary PepMetics® drug discovery platform, which enables the targeting of previously "undruggable" proteins. This technology utilizes unique small molecule scaffolds that mimic peptide structures (α-helices and β-turns) to control protein-protein interactions (PPIs), a key cause of many diseases. By making these challenging targets accessible, PRISM BioLab aims to pioneer new therapies and collaborates with pharmaceutical companies to advance its drug discovery programs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-17 09:30
Major Shareholding Notification
臨時報告書
Japanese 21.0 KB
2025-05-14 09:31
Registration Form
確認書
Japanese 8.7 KB
2025-05-14 09:30
Interim Report
半期報告書-第14期(2024/10/01-2025/09/30)
Japanese 224.7 KB
2024-12-27 07:34
Governance Information
内部統制報告書-第13期(2023/10/01-2024/09/30)
Japanese 22.2 KB
2024-12-27 07:33
Registration Form
確認書
Japanese 8.7 KB
2024-12-27 07:32
Registration Form
有価証券報告書-第13期(2023/10/01-2024/09/30)
Japanese 3.1 MB
2024-12-27 07:31
Post-Annual General Meeting Information
臨時報告書
Japanese 22.1 KB
2024-11-14 07:32
Regulatory News Service
臨時報告書
Japanese 20.8 KB
2024-10-16 10:12
Major Shareholding Notification
臨時報告書
Japanese 20.7 KB
2024-09-10 09:09
Regulatory News Service
臨時報告書
Japanese 19.9 KB
2024-06-24 08:00
Prospectus
訂正有価証券届出書(新規公開時)
Japanese 2.2 MB
2024-06-14 08:00
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 2.3 MB
2024-05-27 08:00
Registration Form
有価証券届出書(新規公開時)
Japanese 4.3 MB

Automate Your Workflow. Get a real-time feed of all 株式会社PRISM BioLab filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for 株式会社PRISM BioLab

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for 株式会社PRISM BioLab via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

curacle co., ltd. Logo
Developing drugs for intractable diseases like diabetes caused by vascular damage and aging.
South Korea
365270
Curanex Pharmaceuticals Inc Logo
Developing botanical drugs for inflammatory diseases, diabetes, and COVID-19.
United States of America
CURX
Curevac Logo
Pioneering mRNA technology to create vaccines and therapies for infectious diseases, cancer, and more.
Germany
CVAC
CureVac N.V. Logo
Pioneering mRNA technology for prophylactic vaccines and novel cancer immunotherapies.
United States of America
CVAC
CURIS INC Logo
Biotech developing innovative cancer therapeutics for hematologic malignancies.
United States of America
CRIS
Curocell Inc. Logo
Biotech developing enhanced CAR-T therapies for cancer using its OVIS™ platform.
South Korea
372320
CYBIN INC. Logo
A clinical-stage firm engineering novel psychedelic drugs for depression and anxiety.
United States of America
CYBN
Cyclerion Therapeutics, Inc. Logo
Developing personalized therapy for TRD with a biofeedback device and anesthetics.
United States of America
CYCN
CYTOKINETICS INC Logo
Late-stage biopharma developing muscle-modulating drugs for heart and neuromuscular diseases.
United States of America
CYTK

Talk to a Data Expert

Have a question? We'll get back to you promptly.